DNA 합성기 시장 - 예측(2026-2031년)

DNA Synthesizer Market is projected to expand at a 15.1% CAGR, attaining USD 1024.688 million in 2031 from USD 440.630 million in 2025.

The DNA synthesizer market is a critical and rapidly evolving segment within the life sciences tools industry, providing the instrumentation and platforms essential for the artificial, de novo creation of oligonucleotides and synthetic genes. These automated systems enable researchers to construct custom DNA sequences from digital inputs, forming the foundational material for a vast range of applications in synthetic biology, therapeutic development, and molecular diagnostics. The market is characterized by a technological shift from traditional phosphoramidite chemistry toward novel enzymatic methods, a move toward benchtop automation, and increasing integration into high-throughput industrial workflows. Growth is driven by the expansive and growing needs of synthetic biology, accelerating drug discovery pipelines, and the demand for faster, more accessible, and higher-fidelity DNA construction.

A primary and powerful driver is the substantial and rising investment in synthetic biology research and its commercial applications. Synthetic biology, which involves the design and construction of new biological parts and systems, is fundamentally dependent on the ability to write DNA as readily as it can be read. Applications span from engineered microbes for industrial biotechnology and agriculture to the development of novel vaccines, cell and gene therapies, and DNA-based data storage. The expansion of this field creates sustained, high-volume demand for synthetic DNA, pushing the need for synthesizers that offer greater throughput, longer construct lengths, and lower error rates to support increasingly ambitious projects.

Closely aligned is the critical role of DNA synthesis in modern drug discovery and therapeutic development. The pharmaceutical and biotechnology industries rely heavily on custom DNA for target validation, antibody development, CRISPR guide RNA synthesis, and the construction of viral vectors for gene therapy. The rise of mRNA therapeutics and vaccines has further amplified this demand, as these modalities require the precise synthesis of long, sequence-optimized RNA templates. DNA synthesizers are integral tools for accelerating these R&D timelines, creating demand for platforms that integrate seamlessly into automated, high-throughput workflows to improve productivity and reduce cycle times in drug development pipelines.

A significant market trend is the growing demand for and innovation in benchtop DNA synthesizers. Traditionally, DNA synthesis was performed by large, centralized core facilities or outsourced to service providers. The advent of compact, user-friendly benchtop instruments is decentralizing synthesis, bringing oligo production directly into individual academic, biotech, and pharmaceutical labs. These systems offer researchers immediate, on-demand access to custom oligonucleotides, significantly speeding experimental iteration and protecting intellectual property. This trend toward lab-scale automation is expanding the total addressable market by placing synthesis capability in the hands of a broader base of end-users.

Technological innovation, particularly the emergence of enzymatic DNA synthesis (EDS), represents a potential paradigm shift within the market. While solid-phase phosphoramidite chemistry has been the industry standard for decades, enzymatic methods offer promising advantages, including reduced use of hazardous solvents, the potential for longer and more accurate synthesis, and a pathway to greener manufacturing. Companies developing EDS platforms are targeting both benchtop and scalable industrial applications, positioning this technology as a key disruptive force that could redefine synthesis economics and capabilities in the coming years.

The market is further fueled by the expanding application of synthetic DNA in molecular diagnostics and personalized medicine. Custom oligonucleotides are essential components for PCR assays, next-generation sequencing panels, and various diagnostic probes. As precision medicine advances and the menu of molecular diagnostics grows, so does the need for reliable, cost-effective synthesis of these specific DNA sequences, supporting steady demand from the diagnostics sector.

Geographically, North America maintains a dominant market position. This leadership is anchored in the region's concentration of leading biotechnology and pharmaceutical companies, top-tier academic research institutions, substantial venture capital funding for synthetic biology startups, and a mature ecosystem for life sciences innovation. The presence of many key synthesizer manufacturers and a culture of early technology adoption further reinforce North America's role as the primary market for advanced DNA synthesis platforms.

The competitive landscape includes established providers of phosphoramidite-based instrumentation, innovative startups pioneering enzymatic synthesis, and large-scale service providers that also develop proprietary synthesis technologies. Competition centers on key performance metrics: synthesis speed, throughput, length capability (read length and throughput), sequence accuracy (error rate), cost per base, and ease of integration into laboratory automation. Strategic activities often involve partnerships with pharmaceutical companies or synthetic biology firms to co-develop tailored solutions.

In conclusion, the DNA synthesizer market is transitioning from a niche tool for oligo production to a central enabling technology for the burgeoning bioeconomy. Its growth trajectory is inextricably linked to the expansion of synthetic biology and the increasing biological digitization of therapeutics and diagnostics. Future market development will be shaped by the successful commercialization and scaling of enzymatic synthesis, continued miniaturization and automation of benchtop systems, and the industry's ability to drive down the cost and increase the fidelity of long DNA constructs. Success for market participants will depend on delivering reliable, scalable, and user-centric platforms that empower researchers to translate genetic designs into physical reality with unprecedented speed and precision.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

DNA Synthesizer Market Segmentation

• By Type
• Benchtop DNA Synthesizer
• Large-Scale DNA Synthesizer
• By Application
• Drug Discovery
• Genetic Engineering
• Clinical Diagnostics
• Others
• By End-User
• Pharmaceutical & Biotech Companies
• Academic & Research Institutes
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations
• 3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. DNA SYNTHESIZER MARKET BY TYPE

• 5.1. Introduction
• 5.2. Benchtop DNA Synthesizer
• 5.3. Large-Scale DNA Synthesizer

6. DNA SYNTHESIZER MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Drug Discovery
• 6.3. Genetic Engineering
• 6.4. Clinical Diagnostics
• 6.5. Others

7. DNA SYNTHESIZER MARKET BY END-USER

• 7.1. Introduction
• 7.2. Pharmaceutical & Biotech Companies
• 7.3. Academic & Research Institutes
• 7.4. Others

8. DNA SYNTHESIZER MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Kilobaser
• 10.2. DNA Script SAS
• 10.3. CSBio
• 10.4. Telesis Bio
• 10.5. Eurofins Genomics LLC
• 10.6. Honya Biotech
• 10.7. Thermo Fisher Scientific
• 10.8. Danaher Corporation
• 10.9. Bioneer Corporation
• 10.10. LGC Biosearch Technologies

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations